Weight Loss Outcomes with Species-Specific Dual GLP-1R/GCGR Agonists in Animal Models
2018
Dual agonism of glucagon-like peptide-1 receptor and glucagon receptor (GLP-1 R/GCGR) was shown to reduce body weight. Species-specific dual GLP-1 R/GCGR agonist peptides (SSDA), structurally based on exendin-4 and carrying a fatty acid side-chain for half-life extension, or the selective GLP-1 R agonist liraglutide (lira) were administered to diet-induced obese (DIO) mice twice daily for 32 days, and to DIO and diabetic cynomolgus monkeys once daily for 43 days. Potencies of the SSDA and lira on mouse and monkey GLP-1 receptors were in the single-digit picomolar range. Body weight change was greater with SSDA than with lira in mice (-21.1 ± 2.1% vs. -12.9 ± 1.4%) and monkeys (-8.2 ± 1.2%; p Disclosure R. Elvert: Employee; Self; Sanofi. M. Bossart: Employee; Self; Sanofi. B. Zhang: None. A. Kannt: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. M. Wagner: Employee; Self; Sanofi. T. Haack: Employee; Self; Sanofi-Aventis Deutschland GmbH. A. Evers: Employee; Self; Sanofi. A. Dudda: Employee; Self; Sanofi. M. Lorenz: None. S. Keil: Employee; Self; Sanofi. P.J. Larsen: Employee; Self; Sanofi.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI